DeepHealth boosts ultrasound AI by integrating See-Mode team
DeepHealth will incorporate See-Mode Technologies' expertise and AI technologies for thyroid and breast ultrasound into its population health solutions following RadNet's acquisition of See-Mode Technologies.
See-Mode's commercially available AI-powered ultrasound detection, characterisation, and reporting solutions for thyroid and breast will be added to DeepHealth's suite of services. These technologies automatically detect and characterise thyroid nodules and breast lesions during ultrasound imaging, aiming to improve diagnostic accuracy and streamline clinical workflows through the generation of standardised reports.
The integration is set against the backdrop of rising global rates of thyroid cancer, which is among the fastest-growing cancer diagnoses worldwide. Alongside breast cancer, it remains a prevalent pathology, particularly impacting women.
Real-world deployment of See-Mode's FDA-cleared thyroid ultrasound AI at selected RadNet imaging centres has already shown operational benefits, with workflow efficiency improvements and enhancements to diagnostic accuracy. The company reported that the inclusion of See-Mode's automated detection and reporting has resulted in up to a 30 per cent reduction in scan time in the centres where it has been piloted.
Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, "Thyroid cancer is one of the fastest growing cancer diagnoses worldwide and, alongside breast cancer, is among the most common cancers affecting women. In the US alone, approximately 20 million ultrasound exams are performed annually for thyroid and breast combined. With ultrasound imaging inherently complex and user and radiologist-dependent, the opportunity to improve care through AI is significant."
Dr. Berger further noted, "Early deployment of See-Mode's FDA-approved thyroid ultrasound AI across a portion of our imaging centers has demonstrated up to a 30% reduction in scan time as a result of increased workflow efficiency from See-Mode's automated detection and reporting. With demand exceeding available appointment slots for many of our over 900 ultrasound units, the increase in capacity created by See-Mode's technology should improve our ability to drive better access and more revenue through RadNet's existing centers. Furthermore, there is already a reimbursement code that makes a portion of our approximately 250,000 annual thyroid ultrasounds eligible for additional reimbursement. We aim to expand these efficiencies to breast screening and other clinical areas in our more than two million annual ultrasound studies. These opportunities will also be sold and marketed by DeepHealth to third parties as we further commercialize the offerings."
See-Mode's AI technologies are currently cleared for commercial distribution in the United States, Canada, Australia, New Zealand, and Singapore. The acquisition supports DeepHealth's stated objective to strengthen its portfolio of AI-driven population health solutions and to address clinical and operational challenges in high-volume care settings.
Dr. Milad Mohammadzadeh, Co-Founder of See-Mode, added: "Ultrasound is complex, time-consuming, and high-volume—exactly where AI can make a difference. By joining RadNet and DeepHealth's combined access to real-world clinical data and expertise at an unprecedented scale, we have an extraordinary platform to build the future of ultrasound."
Echoing these remarks, Kees Wesdorp, President and Chief Executive Officer of RadNet's Digital Health division, said: "We are excited to integrate See-Mode's technology in thyroid and breast ultrasound into DeepHealth's comprehensive portfolio of AI-powered solutions for breast, lung, prostate, and brain, to address clinical and operational challenges in high-volume care settings. The technology and the team's expertise will be the basis for future AI-powered ultrasound solutions that will add to the growth engine of DeepHealth."
According to the information provided, DeepHealth currently operates more than 900 ultrasound units, conducting over two million ultrasound examinations each year. The company expects that the integration of See-Mode's technology will allow it to manage greater demand, improve workflow efficiencies, and address current appointment slot limitations.
Industry sources cited in the release note that in the United States alone, approximately 20 million ultrasound exams are performed each year for thyroid and breast combined. RadNet and DeepHealth aim to capitalise on these volumes by promoting their expanded suite of AI-driven solutions to both internal and third-party customers.
See-Mode's team and technology base in Singapore and Australia will join the DeepHealth operations, contributing their expertise to ongoing and future development of AI-driven ultrasound solutions. This collaboration is expected to facilitate the development of new applications in high-volume diagnostic imaging and to support improved access and outcomes across RadNet's network of imaging centres.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Otago Daily Times
3 days ago
- Otago Daily Times
'For jet lag and insomnia': Psilocybin to be prescribed, melatonin to be sold over-the-counter
The government has signalled melatonin will become available over the counter, and psilocybin - magic mushrooms - will be available for patients with treatment-resistant depression. Psilocybin will still be an "unapproved medicine" but will be able to be granted under the authority of one specific highly experienced psychiatrist. Melatonin is a natural hormone that helps induce sleep, and is used to treat insomnia and jet lag, but has been classified as a prescription-only medicine in New Zealand. It will be available in pharmacies as pills up to 5mg in packs with up to 10 days' supply, or pills up to 3mg. "Modified release doses" - pills, capsules, gels and medical devices which allow the drug to be administered over a specific period - could also be available with dosages of up to 2mg. No specific date has been set for when the changes will take effect. Associate Health Minister David Seymour announced the decisions on Wednesday afternoon, noting they were made by MedSafe rather than politicians. "Certainly I've discussed with some of them ... some of them were very enthusiastic about the melatonin but ultimately they respect that it's a technical decision for MedSafe." He said melatonin would become available once manufacturers began to export it to New Zealand. "You'll be able to go to any pharmacy and buy melatonin for jet lag and insomnia just as soon as it's available over the counter in New Zealand. Part of the purpose of my announcement today is to call on the melatonin manufacturers of the world to apply to bring their products into our country," Seymour said. "When we did this with pseudoephedrine, it was a matter of months before products were on the shelves and I hope we can beat that record. "Kiwis shouldn't be left counting sheep or desperate for options when other countries are already using these medicines. The government is committed to putting patients first ... this is a commonsense decision that will make melatonin more accessible in New Zealand than in many other countries." The change for psilocybin was a huge win for people with depression who had tried everything else, Seymour said. "If a doctor believes psilocybin can help, they should have the tools to try. The psychiatrist involved has previously prescribed psilocybin in clinical trials and will operate under strict reporting and record-keeping requirements." He said it would initially only be available from one specific psychiatrist, but he hoped more would apply. "Psilocybin is a medicine that can treat untreatable depression. It was first researched in the 1950s and '60s and more recently there's been extensive research and approvals by the FDA in the United States to be able to use these types of medicines. "Fair to say it's been driven by people in the profession - there's a lot of people very passionate about this because untreatable depression's an awful thing and there are clinicians who say there's stuff happening in the rest of the world and we need to be part of it." He had never taken either of them, nor pseudoephedrine. "No. No I have not inhaled melatonin but maybe I will. I've had some recent issues with jet lag of my own so hopefully in the future I'll be able to," Seymour said. "I used to go mushroom hunting with my dad as a very small kid, but I don't think we found any." The melatonin changes were confirmed in regulations gazetted by Medsafe group manager Chris James. The psilocybin changes were not yet gazetted, but it will mark the first time psilocybin will be legally available in New Zealand outside of clinical trials.
NZ Autocar
11-06-2025
- NZ Autocar
BYD Sealion 8 seven-seat PHEV SUV coming here
BYD New Zealand has confirmed that the Sealion 8 plug-in hybrid, a three-row SUV, will arrive locally by early 2026 or even late this year. EVs and Beyond talked with BYD NZ country manager, Warren Willmot, who said: 'We're hoping to get it slightly ahead of Australia for December,' said. 'But definitely Q1 2026' at the latest. The BYD Sealion 8 is the brand's largest SUV for export markets, joining the smaller Sealion 7 EV. Built on BYD's latest DM (Dual Mode) 5.0 hybrid platform, it offers two drivetrain options at launch. The entry-level will be DM-i (front-wheel drive) and a dual-motor AWD DM-p variant will also be available. Read our review of BYD Sealion 7 Premium here. Both models use a 1.5-litre turbocharged four-cylinder petrol engine (110kW/220Nm) paired with a front-mounted 200kW electric motor. The DM-p version adds a 141kW rear motor for all-wheel drive and enhanced acceleration. Expect the Sealion 8 DM-p to reach open road speed in a claimed 4.9sec, while the DM-i should manage it in 8.6 seconds. The DM-i uses a 19.0kWh Blade battery while the DM-p comes with fa 35.6kWh unit. These lithium-iron phosphate (LFP) batteries are part of BYD's cell-to-body integration strategy. The result is improved efficiency and structural strength. Pure electric range estimates are pending but should exceed 80km (WLTP) in the DM-p. 'Yes, we'll be taking both drivetrain options — DM-i and DM-p,' Willmot confirmed. 'BEV is probably 12 months after initial launch.' Inside, the BYD Sealion 8 offers a three-row layout for up to seven passengers. Expect also dual digital displays, and climate control across all rows. In DM-p trim, heated and massaging seats in the first and second rows will be standard. Safety items includes adaptive cruise, lane centring, blind spot detection, and autonomous emergency braking. Expect announcements of the BYD Sealion 8's price and specifications for New Zealand closer to launch. It will sit above the Sealion 7 in BYD's local line-up, offering a new electrified option for larger families and fleet buyers.
Techday NZ
05-06-2025
- Techday NZ
DeepHealth boosts ultrasound AI by integrating See-Mode team
DeepHealth will incorporate See-Mode Technologies' expertise and AI technologies for thyroid and breast ultrasound into its population health solutions following RadNet's acquisition of See-Mode Technologies. See-Mode's commercially available AI-powered ultrasound detection, characterisation, and reporting solutions for thyroid and breast will be added to DeepHealth's suite of services. These technologies automatically detect and characterise thyroid nodules and breast lesions during ultrasound imaging, aiming to improve diagnostic accuracy and streamline clinical workflows through the generation of standardised reports. The integration is set against the backdrop of rising global rates of thyroid cancer, which is among the fastest-growing cancer diagnoses worldwide. Alongside breast cancer, it remains a prevalent pathology, particularly impacting women. Real-world deployment of See-Mode's FDA-cleared thyroid ultrasound AI at selected RadNet imaging centres has already shown operational benefits, with workflow efficiency improvements and enhancements to diagnostic accuracy. The company reported that the inclusion of See-Mode's automated detection and reporting has resulted in up to a 30 per cent reduction in scan time in the centres where it has been piloted. Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, "Thyroid cancer is one of the fastest growing cancer diagnoses worldwide and, alongside breast cancer, is among the most common cancers affecting women. In the US alone, approximately 20 million ultrasound exams are performed annually for thyroid and breast combined. With ultrasound imaging inherently complex and user and radiologist-dependent, the opportunity to improve care through AI is significant." Dr. Berger further noted, "Early deployment of See-Mode's FDA-approved thyroid ultrasound AI across a portion of our imaging centers has demonstrated up to a 30% reduction in scan time as a result of increased workflow efficiency from See-Mode's automated detection and reporting. With demand exceeding available appointment slots for many of our over 900 ultrasound units, the increase in capacity created by See-Mode's technology should improve our ability to drive better access and more revenue through RadNet's existing centers. Furthermore, there is already a reimbursement code that makes a portion of our approximately 250,000 annual thyroid ultrasounds eligible for additional reimbursement. We aim to expand these efficiencies to breast screening and other clinical areas in our more than two million annual ultrasound studies. These opportunities will also be sold and marketed by DeepHealth to third parties as we further commercialize the offerings." See-Mode's AI technologies are currently cleared for commercial distribution in the United States, Canada, Australia, New Zealand, and Singapore. The acquisition supports DeepHealth's stated objective to strengthen its portfolio of AI-driven population health solutions and to address clinical and operational challenges in high-volume care settings. Dr. Milad Mohammadzadeh, Co-Founder of See-Mode, added: "Ultrasound is complex, time-consuming, and high-volume—exactly where AI can make a difference. By joining RadNet and DeepHealth's combined access to real-world clinical data and expertise at an unprecedented scale, we have an extraordinary platform to build the future of ultrasound." Echoing these remarks, Kees Wesdorp, President and Chief Executive Officer of RadNet's Digital Health division, said: "We are excited to integrate See-Mode's technology in thyroid and breast ultrasound into DeepHealth's comprehensive portfolio of AI-powered solutions for breast, lung, prostate, and brain, to address clinical and operational challenges in high-volume care settings. The technology and the team's expertise will be the basis for future AI-powered ultrasound solutions that will add to the growth engine of DeepHealth." According to the information provided, DeepHealth currently operates more than 900 ultrasound units, conducting over two million ultrasound examinations each year. The company expects that the integration of See-Mode's technology will allow it to manage greater demand, improve workflow efficiencies, and address current appointment slot limitations. Industry sources cited in the release note that in the United States alone, approximately 20 million ultrasound exams are performed each year for thyroid and breast combined. RadNet and DeepHealth aim to capitalise on these volumes by promoting their expanded suite of AI-driven solutions to both internal and third-party customers. See-Mode's team and technology base in Singapore and Australia will join the DeepHealth operations, contributing their expertise to ongoing and future development of AI-driven ultrasound solutions. This collaboration is expected to facilitate the development of new applications in high-volume diagnostic imaging and to support improved access and outcomes across RadNet's network of imaging centres.
